Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy shows remarkable efficacy in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). HBI0101, a novel second generation optimized anti-BCMA CAR T-cell therapy, was developed in an academic setting. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Asherie, Nathalie, Kfir-Erenfeld, Shlomit, Avni, Batia, Assayag, Miri, Dubnikov, Tatyana, Zalcman, Nomi, Lebel, Eyal, Zimran, Eran, Shaulov, Adir, Pick, Marjorie, Cohen, Yael, Avivi, Irit, Cohen, Cyrille, Gatt, Moshe E., Grisariu, Sigal, Stepensky, Polina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316256/
https://www.ncbi.nlm.nih.gov/pubmed/36200421
http://dx.doi.org/10.3324/haematol.2022.281628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316256/
https://www.ncbi.nlm.nih.gov/pubmed/36200421
http://dx.doi.org/10.3324/haematol.2022.281628

Ejemplares similares